Establishment Labs Holdings (ESTA) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.32

Estimate

-$0.30

Surprise

-5.9%

Score at report (before → after)

5.2 → 5.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Establishment Labs Holdings (ESTA) reported a wider loss than forecast — diluted EPS of -$0.32 against the -$0.30 estimate (a 5.9% shortfall). TrendMatrix's engine moved from Sell (5.2/10) to Hold at 5.4/10 after the report — the engine's score rose despite the miss.

TrendMatrix currently rates ESTA Sell at 6.1/10.

2 of the last 4 quarters beat the estimate; this quarter's -5.9% surprise compares with a +18.8% four-quarter average. Next scheduled report: 2026-11-04.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$74.27

Price target

$89.13

Stop

$69.07

Upside to target

+20.0%

Reward-to-risk

2.1:1

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Devices

Market cap

$2.15B

P/E (fwd)

1205.0

52-week range

$36.53–$97.59

Off 52-week high

23.9%

RSI (14)

44

Volume vs avg

0.39×

Score today

6.1/10